Related Experiment Videos
Fungal pneumonia in transplant recipients
1Department of Infectious Diseases, St Luke's Episcopal Hospital, Houston, Texas 77030.
Abstract:
Fungal pneumonia is an infrequent but devastating complication of solid organ transplantation. The suspicion of fungal pulmonary infections caused by the dimorphic fungi is based on particular knowledge about the recipient's past or present residence in an endemic area. Some fungi, such as Cryptococcus neoformans, Candida sp and Mucor sp are associated with concomitant diabetes mellitus. The level of immunosuppressive therapy is also a major predisposing factor. For some fungi, such as Coccidioides immitis and C neoformans, serologic tests may assist in diagnosis. For aspergillus, Candida sp and Mucor sp culture evidence is not sufficient to determine pulmonary involvement since these fungi may be nonpathogenic saprophytes. Histopathologic proof is required. In patients with abnormal host defenses, treatment of fungal pneumonia is complex. In solid organ transplant recipients it is made more difficult by drug interactions with cyclosporine. Amphotericin B exhibits synergistic nephrotoxicity with cyclosporine and ketoconazole competes with cyclosporine for hepatic metabolism in an unpredictable manner that may result in increased cyclosporine toxicity.
Insights
Fungal pneumonia is a rare but serious complication after solid organ transplantation. Diagnosis and treatment are complex due to immunosuppression and drug interactions, particularly with cyclosporine.
Area of Science:
- Medicine
- Infectious Diseases
- Transplantation
Background:
- Fungal pneumonia is an infrequent yet severe complication in solid organ transplant (SOT) recipients.
- Risk factors include residence in endemic areas, co-existing diabetes mellitus, and the level of immunosuppressive therapy.
- Specific fungi like Cryptococcus neoformans, Candida sp, and Mucor sp are frequently implicated.
Purpose of the Study:
- To review the diagnostic challenges and treatment complexities of fungal pneumonia in SOT recipients.
- To highlight the impact of immunosuppression and drug interactions on managing these infections.
Main Methods:
- Literature review focusing on fungal pulmonary infections in SOT patients.
- Analysis of diagnostic criteria, including serologic tests and histopathology.
- Evaluation of treatment strategies and drug interactions with immunosuppressants like cyclosporine.
Main Results:
- Diagnosis requires careful consideration of endemic exposures and host factors.
- Serologic tests are useful for some fungi (e.g., Coccidioides immitis, C neoformans), but not sufficient for others (e.g., Aspergillus, Candida, Mucor).
- Histopathologic proof is essential for definitive diagnosis of pulmonary involvement.
- Treatment is complicated by drug interactions, such as the nephrotoxicity of Amphotericin B and unpredictable metabolism of ketoconazole with cyclosporine.
Conclusions:
- Fungal pneumonia in SOT recipients presents unique diagnostic and therapeutic challenges.
- Management requires a multidisciplinary approach, considering fungal species, host immunity, and potential drug toxicities.
- Careful monitoring for drug interactions, especially with cyclosporine, is critical for successful outcomes.